Cisatracurium in a myasthenic patient undergoing thymectomy

Canadian Journal of Anaesthesia

Volumn 46, Issue 8, 1999, Pages 779-782

  Baraka, Anis ^a   Siddik, Sahar ^a   Kawkabani, Nadine ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINERGIC RECEPTOR; CISATRACURIUM; DIAZEPAM; FENTANYL; LIDOCAINE; NEOSTIGMINE; PREDNISONE; PYRIDOSTIGMINE;

AGED; ANESTHESIA MECHANISM; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; ELECTROMYOGRAPHY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MYASTHENIA; NEUROMUSCULAR BLOCKING; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; THYMECTOMY;

EID: 0032884970     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03013915     Document Type: Article

References (18)

1. Simpson JA. Myasthenia gravis a new hypothesis. Scott Med J 1960; 5: 419-36.
2. Lindstrom JM, Lennon VA, Seybold ME, Whittingbam S. Experimental autoimmune myasthenia gavis and myasthenia gravis: biochemical and immunochemical aspects. Ann NY Acad Sci 1976; 274: 254-74.
3. Elmqvist D, Hofmann WW, Kugelberg J, Quastel DMJ. An electrophysiological investigation of neuromuscular transmission in myasthenia gravis. J Physiol (Lond) 1964; 174: 417-34.
4. Grob D, Namba T. Characteristics and mechanism of neuromuscular block in myasthenia gravis. Ann NY Acad Sci 1976; 274: 143-73.
5. Eisenkraft JB, Book WJ, Mann SM, Papatestas AE. Hubbard M. Resistance to succinylcholine in myasthenia gravis: a dose-response study. Anesthesiology 1988; 69: 760-63.
6. Baraka A. Anaesthesia and myasthenia gravis. Can J Anaesth 1992; 39: 476-86.
7. Ali HH, Savarese JJ, Basta SJ, Sunder N, Gionfriddo M, Lineberry C. Clinical pharmacology of atracurium - a new intermediate acting nondepolarizing relaxant. Seminars in Anesthesia 1982; 1: 57-62.
8. Baraka A, Dajani A. Atracurium in myasthenics undergoing thymectomy. Anesth Analg 1984; 63: 1127-30.
9. Belmont MR, Lien CA, Quessy S, et al. The clinical neuromuscular pharmacology of 51 W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 1995; 82: 1139-45.
10. Berrib-Aknin S, Morel E, Raimond F, et al. The role of the thymus in myasthenia gravis: immunohistological and immunological studies in 115 cases. Ann NY Acad Sci 1987; 505: 50-70.
11. Woolf AL. Morphology of the myasthenic neuromuscular junction. Ann NY Acad Sci 1966; 135: 35-58.
12. Engel AG, Santa T. Histometric analysis of the ultrastructure of the neuromuscular junction in myasthenia gravis and in the myasthenic syndrome. Ann NY Acad Sci 1971; 183: 46-63.
13. Drachman DB. Myasthenia Gravis. (First of two parts) N Engl J Med 1978; 298: 136-42.
14. Baraka A. Suxamethonium block in the myasthenic patient. Correlation with plasma cholinesterase. Anaesthesia 1992; 47: 217-9.
15. Baraka A. Onset of neuromuscular block in myasthenic patients (Letter). Br J Anaesth 1992; 69: 227-8.
16. Miller JD, Rosenbaum H. Muscle diseases. In: Benumof JL (Ed.). Anesthesia and Uncommon Diseases, 4th ed. Philadelphia: W.B. Saunders Company, 1998: 316-97.
17. Baraka A, Taha S, Yazbeck V, Rizkallah P. Vecuronium block in the myasthenic patient. Influence of anti-cholinesterase therapy. Anaesthesia 1993; 48: 588-90.
18. Baraka A, El-Zayat F, Abdel-Rahman Y, Awad E. Mode of action of tubocurarine and suxamethonium in different species. U.A.R. Journal of Physiological Sciences 1965; 1: 107-19.